Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015)
Ημερομηνία
2017Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Aims: To review and assess the definitions of drug resistance and the evidence supporting treatment for drug resistant overactive bladder/detrusor overactivity (OAB/DO). Methods: Evidence review of the extant literature and consensus of opinion was used to derive the summary recommendations. Results: Drug resistance or drug refractory status has been inconsistently defined and reported in current evident sources. Recent publications use some correlation of lack of efficacy and or experienced side effects to define drug resistance. Algorithms based upon these definitions largely relate to the appropriate use of neuromodulation or botulinum neurotoxin, based upon patient selection and patient choice. Current treatment pathways are hampered by inability to consistently profile patients to optimize management, particularly after failure of initial pragmatic treatment. Conclusions: Further research is recommended to better identify patient phenotype for purposes of directing optimized therapy for OAB/DO. Current treatment algorithms are influenced by extensive data generated from recent neuromodulation and botulinum neurotoxin trials. © 2017 Wiley Periodicals, Inc.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Optimal bladder diary duration for patients with suprapontine neurogenic lower urinary tract dysfunction
Konstantinidis C., Kratiras Z., Samarinas M., Skriapas K. (2016)Purpose: To identify the minimum bladder diary's length required to furnish reliable documentation of LUTS in a specific cohort of patients suffering from neurogenic urinary dysfunction secondary to suprapontine pathology. ... -
Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA)
Mangera, A.; Andersson, K. E.; Apostolidis, A.; Chapple, C.; Dasgupta, P.; Giannantoni, A.; Gravas, S.; Madersbacher, S. (2011)Context: The use of botulinum toxin A (BoNTA) in the treatment of lower urinary tract dysfunction has expanded in recent years and the off-licence usage list includes neurogenic detrusor overactivity (NDO), idiopathic ... -
Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Cosimo De Nunzio, Benjamin Brucker, Thomas Bschleipfer, et al. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. Eur Urol 2021;79:492–504
De Nunzio C., Brucker B., Bschleipfer T., Cornu J.-N., Drake M.J., Fusco F., Gravas S., Oelke M., Peyronnet B., Tutolo M., van Koeveringe G., Madersbacher S. (2021)[No abstract available]